Recently, two randomized controlled trials (RCTs) demonstrated that tirzepatide, a dual GLP-1/GIP receptor agonists, reduced the AHI and hypoxic burden, and improved sleep-related patient-reported outcomes among individuals with moderate-to-severe OSA [24]
Cumulative adherence at three years was 51.2% (61 238/119 657) and 53.6% (205 973/384 489) for the GLP-1 receptor agonist and SGLT-2 inhibitor groups, respectively (see supplementary table S7)
GHK-Cu modulates genes involved in melanin production and tissue remodeling, gradually improving the appearance of old skin damage
Appetite Control and Craving Reduction These medications act on appetite centers in the brain, helping patients feel satisfied with smaller portions and reducing emotional eating patterns
Reported Risks and Side Effects Gastrointestinal Issues: These may include nausea, vomiting, bloating, diarrhea, constipation, and slowed gastric emptying, which can sometimes lead to discomfort or changes in appetite
Olive oil drizzle, avocado, or a sprinkle of nuts or seeds